![[Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer].](/static/images/no-image.png)
Journal article
[Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer].
- Afshar-Oromieh A Klinik für Nuklearmedizin, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz. ali.afshar@insel.ch.
- Alberts I Klinik für Nuklearmedizin, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz.
- Sachpekidis C Klinik für Nuklearmedizin, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz.
- Rominger A Klinik für Nuklearmedizin, Inselspital Bern, Freiburgstraße 18, 3010, Bern, Schweiz.
- 2019-11-10
Published in:
- Der Urologe. Ausg. A. - 2019
PET/CT
Radioligand
Radiotherapy
Recurrence
Tumor marker
Humans
Male
Membranes
Neoplasm Recurrence, Local
Positron Emission Tomography Computed Tomography
Prostate-Specific Antigen
Prostatic Neoplasms
English
BACKGROUND
Since their clinical introduction in 2011, PSMA-PET/CT (PSMA: prostate-specific membrane antigen) as well as PSMA therapy of prostate cancer (PC) have spread rapidly worldwide.
OBJECTIVES
To summarize the current knowledge about both PSMA-PET/CT and PSMA therapy of PC.
METHODS
The knowledge derived from the literature as well as the authors' experiences were collected in this review.
RESULTS
PSMA-PET/CT demonstrates a very high sensitivity and specificity for the detection of recurrent PC as well as for the primary staging of intermediate- and high-risk PC. PSMA therapy shows promising results in third-line treatment for patients with castration-resistant, metastatic PC.
CONCLUSIONS
PSMA-PET/CT is meanwhile established as the gold standard for the detection of recurrent PC and is in the process of assuming the same role for primary staging of intermediate- to high-risk PC. PSMA therapy serves as a promising third-line therapy in an increasing number of centers.
Since their clinical introduction in 2011, PSMA-PET/CT (PSMA: prostate-specific membrane antigen) as well as PSMA therapy of prostate cancer (PC) have spread rapidly worldwide.
OBJECTIVES
To summarize the current knowledge about both PSMA-PET/CT and PSMA therapy of PC.
METHODS
The knowledge derived from the literature as well as the authors' experiences were collected in this review.
RESULTS
PSMA-PET/CT demonstrates a very high sensitivity and specificity for the detection of recurrent PC as well as for the primary staging of intermediate- and high-risk PC. PSMA therapy shows promising results in third-line treatment for patients with castration-resistant, metastatic PC.
CONCLUSIONS
PSMA-PET/CT is meanwhile established as the gold standard for the detection of recurrent PC and is in the process of assuming the same role for primary staging of intermediate- to high-risk PC. PSMA therapy serves as a promising third-line therapy in an increasing number of centers.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1007/s00120-019-01067-x
- PMID 31705143
- Persistent URL
- https://sonar.ch/global/documents/279309
Statistics
Document views: 21
File downloads: